Skip to main content

Table 1 Basic clinical characteristics of 90 participants

From: The effect of haptoglobin genotype on the association of asymmetric dimethylarginine and DDAH 1 polymorphism with diabetic macroangiopathy

Variable

Hp 1-1

Hp 2-1

Hp 2-2

P value

N

30

30

30

–

Age (years)

57.1 ± 10.7

56.6 ± 14.0

57.0 ± 11.5

0.978

Male/female (n)

24/6

18/12

19/11

0.170

BMI (kg/m2)

25.0 ± 2.8

24.2 ± 2.8

25.2 ± 4.6

0.722

SBP (mmHg)

130 (120, 150)

130 (120, 150)

130 (120, 135)

0.281

DBP (mmHg)

80 (70, 86)

80 (70, 90)

80 (70, 85)

0.996

Duration of diabetes (years)

10.5

(7.0, 15.0)

10.0

(4.0, 14.0)

10.0

(6.0, 15.0)

0.721

HbA1c (%)

8.1 (7.1, 10.1)

8.3 (7.6, 10.9)

8.6 (6.9, 9.6)

0.629

HbA1c [mmol/mol]

65 (54, 87)

67 (60, 96)

70 (52, 81)

 

Total cholesterol (mmol/L)

4.4 ± 0.9

4.6 ± 0.9

4.6 ± 1.0

0.497

Triglycerides (mmol/L)

1.4 ± 0.9

1.6 ± 0.9

1.7 ± 1.0

0.104

HDL-C (mmol/L)

1.0 ± 0.3

1.1 ± 0.3

1.0 ± 0.2

0.886

LDL-C (mmol/L)

2.6 ± 0.8

2.7 ± 0.8

2.8 ± 0.7

0.778

Diabetic macroangiopathy

17 (56.67%)

14 (46.67%)

13 (43.33%)

0.304

  1. Data are shown as n (%), mean ± standard deviation, or median (interquartile range).
  2. Hp haptoglobin, Hp 1 carriers Hp 1–1 and Hp 2 − 1, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HbA1c hemoglobin A1c, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol